Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点目标入组 40 人开始时间: 2007年2月14日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. age 18 years 2. active but clinically stable plaque psoriasis resistant to traditional treatments 3. involvement of at least 10 percent of the body surface area 4. minimal psoriasis area-and-severity index 21 of 10 indicating moderate to severe psoriasis during the screening period 5. at least once previous phototherapy or systemic psoriasis therapy or eligibility for such therapy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. pregnancy and nursing 2. guttate, erythrodernic, or pustular psoriasis at the time of screening 3. previous treatment with etanercept or anti-TNF antibodies 4. previous treatment with anti-CD4 antibodies or interleukin-2-diphtheria-toxin fusion protein within the previous six months 5. previous treatment with biologic or investigational drug, psoralen-ultaviolet A phototherapy, systemic corticosteroids, or systemic psoriasis therapy within the previous four weeks 6. previous treatment with ultraviolet B phototherapy, topical corticosteroids, vitamin A or D analogues, or anthralin within the previous two weeks antibiotic treatment within the previous week 7. other inflammatory, systemic or skin disease 8. recent vaccination

发起方

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI